<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268875</url>
  </required_header>
  <id_info>
    <org_study_id>RBHP 2019 SOUTEYRAND</org_study_id>
    <secondary_id>2019-A02305-52</secondary_id>
    <nct_id>NCT04268875</nct_id>
  </id_info>
  <brief_title>Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT</brief_title>
  <acronym>RESTO</acronym>
  <official_title>Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Corelab ISIT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The statistical risk of intrastent stenosis has fallen considerably with the emergence of&#xD;
      latest generation coated stents (drug-eluting stents: DES). The number and clinical lifespan&#xD;
      of stents implanted over the last twenty-five years, however, explain the fact that&#xD;
      restenosis remains a not unusual clinical problem which is expressed as a recurrence of&#xD;
      angina or of an acute coronary syndrome (ACS).&#xD;
&#xD;
      The mechanisms involved in this restenosis are multifactorial in nature and differ depending&#xD;
      on the type of stent and the time since the restenosis occurred. In symptomatic stent&#xD;
      restenosis (angina or acute coronary syndrome), a further angioplasty is usually required,&#xD;
      occasionally on an emergency basis. Coronary angiography is often not capable of explaining&#xD;
      the mechanical causes of this complication.&#xD;
&#xD;
      Optical coherence tomography (OCT), a high-resolution endocoronary imaging technique can&#xD;
      assist in the understanding of the mechanism of restenosis and guide treatment. OCT during&#xD;
      angiography provides a detailed analysis of the stents and potential complications: the&#xD;
      presence of neoatherosclerosis with or without plaque rupture, intimal hyperplasia, stent&#xD;
      under-deployment, stent fracture and distal or proximal progression of the atherosclerosis.&#xD;
&#xD;
      The investigators propose a prospective, multicentre study of all cases of intrastent&#xD;
      restenosis, examined by angiography, causing clinical features involving stable angina and&#xD;
      acute coronary syndrome. The coronary artery involved will be routinely studied by OCT for a&#xD;
      mechanical cause of the intrastent restenosis. The routine use of intrastent OCT may assist&#xD;
      in the understanding of causes of restenosis and in the decision on appropriate treatment.&#xD;
      There are several possible treatments for restenosis, including balloon angioplasty, coated&#xD;
      balloon angioplasty, stenting or aorto-coronary bypass graft surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All stented coronary artery patients hospitalised for stable angina or an ACS requiring a&#xD;
      further coronary angiogram (regardless of time since implantation or type of the initial&#xD;
      stent) identified to have intrastent restenosis during coronary angiography will be included&#xD;
      after being informed and obtaining their informed written consent.&#xD;
&#xD;
        -  For cases of stable angina the OCT the will be performed immediately with insertion of&#xD;
           the probe distal to the area being studied and then automatic retraction of the fibre&#xD;
           during injection of the contrast medium.&#xD;
&#xD;
        -  For ACS, the OCT will be performed immediately or on a deferred basis at the discretion&#xD;
           of the operator.&#xD;
&#xD;
        -  For critical lesions which prevent the OCT fibre passing across the lesion, &quot;soft&quot;&#xD;
           predilatation with a 2 mm or smaller balloon is permitted.&#xD;
&#xD;
        -  Practical conduct of the OCT:&#xD;
&#xD;
             -  Pullback at baseline state and analysis of the stent with a 5 mm margin proximal&#xD;
                and distal to the lesion.&#xD;
&#xD;
             -  OCT analysis: under-deployment of the stent (expansion &lt; 80% of the reference mean&#xD;
                surface area), neoatherosclerosis with or without rupture, homogeneous or&#xD;
                non-homogeneous hyperplasia, stent fracture and proximal or distal progression of&#xD;
                the atherosclerosis.&#xD;
&#xD;
             -  Final pullback in cases of a new angioplasty (balloon angioplasty, angioplasty with&#xD;
                a coated balloon or stenting).&#xD;
&#xD;
        -  The OCT investigations will be anonymised and registered in their original format with a&#xD;
           view to centralised reading (Corelab ISIT, UMR 6284-CNRS, Clermont-Ferrand University).&#xD;
&#xD;
        -  The angiography records will be submitted for reading by a panel blinded to the OCT for&#xD;
           the purposes of demonstrating the added value of OCT in the fine details of diagnosis&#xD;
           and the impact of a treatment decision. The angiograms will be reviewed in a centralised&#xD;
           analytical laboratory, which will re-read the procedures blind.&#xD;
&#xD;
        -  Patients will be followed up via telephone contact or visit one year after inclusion&#xD;
           into the study to record any complications which have developed (possible myocardial&#xD;
           infarction, reason, any new revascularisation of the target lesion or another artery and&#xD;
           reason for this, any deaths and their causes).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characteristics of morphological abnormalities, seen on OCT on millimetre sections of the whole stented segment (5 mm proximally and distally to the stent), potentially responsible for the intrastent restenosis</measure>
    <time_frame>day 0</time_frame>
    <description>Under-deployment of the stent with percentage under-deployment is defined when the minimum intrastent surface area is less than 80% of the reference surface area.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of morphological abnormalities, seen on OCT on millimetre sections of the whole stented segment (5 mm proximally and distally to the stent), potentially responsible for the intrastent restenosis</measure>
    <time_frame>day 0</time_frame>
    <description>Homogeneous or non-homogeneous intimal hyperplasia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of morphological abnormalities, seen on OCT on millimetre sections of the whole stented segment (5 mm proximally and distally to the stent), potentially responsible for the intrastent restenosis</measure>
    <time_frame>day 0</time_frame>
    <description>Presence of neoatherosclerosis, with or without rupture.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of morphological abnormalities, seen on OCT on millimetre sections of the whole stented segment (5 mm proximally and distally to the stent), potentially responsible for the intrastent restenosis</measure>
    <time_frame>day 0</time_frame>
    <description>Stent fracture .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of morphological abnormalities, seen on OCT on millimetre sections of the whole stented segment (5 mm proximally and distally to the stent), potentially responsible for the intrastent restenosis</measure>
    <time_frame>day 0</time_frame>
    <description>Progression of the proximal or distal atherosclerosis .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>time to onset of intrastent restenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>past history of angioplasty</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>coronary artery bypass grafting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>multi-vessel disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>prosthetic valve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>chronic renal failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>atrial fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>valve disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>vascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>CVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical data</measure>
    <time_frame>day 0</time_frame>
    <description>TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>day 0</time_frame>
    <description>hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>day 0</time_frame>
    <description>dyslipidaemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>day 0</time_frame>
    <description>diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>day 0</time_frame>
    <description>family history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>day 0</time_frame>
    <description>overweight (BMI &gt; 25)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>day 0</time_frame>
    <description>smoking habit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sample</measure>
    <time_frame>day 0, day 365</time_frame>
    <description>Measure of LDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sample</measure>
    <time_frame>day 0, day 365</time_frame>
    <description>Measure of HDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sample</measure>
    <time_frame>day 0, day 365</time_frame>
    <description>Measure of triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sample</measure>
    <time_frame>day 0, day 365</time_frame>
    <description>Measure of HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sample</measure>
    <time_frame>day 0, day 365</time_frame>
    <description>Measure of creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sample</measure>
    <time_frame>day 0, day 365</time_frame>
    <description>Measure of renal clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New revascularisation events</measure>
    <time_frame>day 365</time_frame>
    <description>new revascularisation event in the target lesion or another artery, myocardial infarctions, deaths and causes of events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>In-stent Restenosis</condition>
  <arm_group>
    <arm_group_label>OCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient witch coronary artery disease who has been stented and is hospitalised for stable angina or acute coronary syndrome requiring a further coronary angiogram (regardless of time since implantation or type of the initial stent.&#xD;
- Identification of intrastent restenosis during coronary angiography and realisation of an immediate or deferred OCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical Coherence Tomography (OCT)</intervention_name>
    <description>The OCT fibre is an optical fibre catheter containing a lens located at its extremity and positioned distal to the arterial segment to be examined. This is an intracoronary, very high-resolution section technique based on absorption and reflection of close infrared light by stents and tissues.&#xD;
OCT analysis is performed during a usual coronary angiography procedure. It is a common technique already used and recommended for intrastent restenosis to establish the mechanism of the process. No new product is being tested. The examination performed is the same.</description>
    <arm_group_label>OCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women, aged 18 years and over.&#xD;
&#xD;
          -  Uncoated, coated or bioresorbable stent restenosis, defined by lumen obstruction of&#xD;
             over 50% in the stent and/or within 5 mm proximal or distal to the stent found on&#xD;
             coronary angiography.&#xD;
&#xD;
          -  Patients treated for an acute coronary syndrome in which restenosis is suspected. It&#xD;
             is recommended that OCT be performed after restoring TIMI grade 3 coronary flow in the&#xD;
             initial investigation or in a later review at &lt; 7 days.&#xD;
&#xD;
          -  Patient informed consent.&#xD;
&#xD;
          -  Subscription to a social security system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Technical inability to perform the OCT (distal lesions, severe chronic renal failure).&#xD;
&#xD;
          -  Contraindication to the use of ABBOTT systems when insertion of any type of catheter&#xD;
             represents a risk to the patient. The contraindications include the following:&#xD;
&#xD;
               -  Bacteraemia or septicaemia&#xD;
&#xD;
               -  Significant coagulation system abnormalities&#xD;
&#xD;
               -  Patients in whom coronary artery spasm has been diagnosed&#xD;
&#xD;
               -  Patients who do not meet the criteria for coronary artery bypass grafting&#xD;
&#xD;
               -  Patients who do not meet the criteria for percutaneous coronary angioplasty&#xD;
&#xD;
               -  Severe haemodynamic shock or instability&#xD;
&#xD;
               -  Total occlusion&#xD;
&#xD;
          -  Life expectancy of under one year for non-cardiac reasons.&#xD;
&#xD;
          -  Pregnant or breast-feeding women or women who are fertile and not taking appropriate&#xD;
             contraceptives.&#xD;
&#xD;
          -  Patients under legal protection or guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Géraud Souteyrand</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise Laclautre</last_name>
    <phone>334.73.754.963</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Université- Hôpital Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tom ADRIAENSSENS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise Laclautre</last_name>
      <phone>0473754963</phone>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Géraud Souteyrand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique la Roseraie</name>
      <address>
        <city>Aubervilliers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hakim BENHAMER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Avignon</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marine Quillot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Meneveau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Edouard Gerbaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Martine Gilard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital privé saint Martin</name>
      <address>
        <city>Cauro</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-François Morelle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier les Hôpitaux de Chartres</name>
      <address>
        <city>Chartres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Grégoire RANGE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stéphanie MARLIERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hervé POULIQUEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric VAN BELLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Joseph Saint Luc</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sylvain RANC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civiles Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles RIOUFOL</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brahim HARBAOUI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marc LAINE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benoît LATTUCA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique les fleurs</name>
      <address>
        <city>Ollioules</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe COMMEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johanne SILVAIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel TEIGER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios SIDERIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas AMABILE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sébastien LEVESQUE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Hilaire</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthieu GODIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick OHLMANN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur Toulouse</name>
      <address>
        <city>Toucy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin HONTON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thibault LHERMUSIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpitaux de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe SAINT-ETIENNE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lorenz RABER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUV de Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Olivier MULLER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>In-stent restenosis</keyword>
  <keyword>optical coherence tomography (OCT)</keyword>
  <keyword>coronary angiography</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

